Join Now!
Home  Top Stories  Sports  Entertainment  Health News  Business  Personal Finance 
Real Estate  Business Finance  Insurance  Consulting 
Tax News  Forum



Featured Articles



How much should you be saving on Health Insurance?




ADHD – Daytrana Methylphenidate Patch approved by the FDA for Treatment of Attention Deficit Hyperactivity Disorder in Children

April 11th, 2006

ADHD – Daytrana Methylphenidate Patch approved by the FDA for Treatment of Attention Deficit Hyperactivity Disorder in Children

Transdermal Patches

The Food and Drug Administration approved the transdermal skin patch that will deliver the drug methylphenidate, which is a central nervous system (CNS) stimulant.  It was approved on April 6th for treating children with Attention Deficit Hyperactivity Disorder (ADHD) in children ranging from 6 to 12 years old.  The commercial drug name for the methylphenidate patch is called Daytrana and is the first transdermal skin patch for treating ADHD.  Daytrana is manufactured for Shire US. Inc., by Noven Pharmaceuticals Inc.

"Daytrana provides an alternative route of administration for methylphenidate in children with ADHD,” said Dr. Galson who is the FDA’s Director of the Center for Drug Evaluation and Research.


According to the FDA press release there are approximately 3 – 7 percent of school aged children that have ADHD.  Symptoms of ADHD include inability to concentrate, hyperactivity and impulsiveness.  An ADHD child has problems with school, getting along with their family and peers and may also have low self-esteem.


The Daytrana patch is worn on the hip for nine hours each day.  The amount of time that a patch is worn can vary depending on how much methylphenidate is needed for the treatment of ADHD.

Side effects of using the Daytrana patch are insomnia, blurred vision, mild skin irritation or a rash.  The child is also more susceptible to slowed weight gain and slowed growth of height.  Children that have cardiac abnormalities should not use the Daytrana patch because it further increases the risk of sudden death.


Daytrana can cause children who have a problem with anxiety to make it even worse and should not use this medication.  There is a chance for allergic reactions that would make it not useable.  It is not recommend for children with glaucoma.  The child should not combine a monoamine oxidase inhibitor (MAOI) and the use of the Daytrana patch at the same time.  A child with Tourette’s syndrome should not take this medication either.

Comment on this Article at our Forum

Submit your own Article

Attention Deficit ADHD Special Topic 

  RSS Attention Deficit Disorder News

  RSS Feed to our health News

  RSS Feed to all of our News

Add to Google Add to My AOL
Add to My Yahoo! Subscribe with Pluck RSS reader
Subscribe in NewsGator Online
Add this feed to Your C-Net

Nicole Wilson
Best Syndication

Books on ADHD

Keywords and Misspellings: ADD ADHD attention deficit disorder atention defecit attension dissorder A.D.H.D. diseese treetment simptoms symptims drugs diagnoses daytona drug patch daytrayna datrayna daytrena daytreena

Important:  The material on Best Syndication is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness program.

About   Contact   Site Map

Copyright 2005 Best Syndication                   Last Updated Saturday, July 10, 2010 09:48 PM